1. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. (January 2022) Authors: Vermeire, Severine; Lakatos, Peter L; Ritter, Timothy; Hanauer, Stephen; Bressler, Brian; Khanna, Reena; Isaacs, Kim; Shah, Saumin; Kadva, Alysha; Tyrrell, Helen; Oh, Young S; Tole, Swati; Chai, Akiko; Pulley, Jennifer; Eden, Christopher; Zhang, Wenhui; Feagan, Brian G; Abraham, Philip; Acir Crip... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 1(2022) Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P055 Vedolizumab Treatment Persistence up to 5 Years: Post hoc Analysis in Vedolizumab-Naïve Patients From the GEMINI Long-Term Safety Study. (December 2019) Authors: Loftus, Edward; Peyrin-Biroulet, Laurent; Vermeire, Séverine; Adsul, Sashi; Demuth, Dirk; Mokiou, Stella; Patel, Haridarshan; Lirio, Richard Journal: American journal of gastroenterology Issue: Volume 114:2019 Supplement (2019)Abstracts 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Utility and Safety of Balloon‐Assisted Enteroscopy in Small Bowel Crohn's Disease: Single ‐ Center Cohort Experience: 667. (October 2016) Authors: Deepak, Parakkal; Quinn, Kevin P.; Fletcher, Joel G.; Barlow, John; Loftus, Edward; Alexander, Jeffrey A.; Rajan, Elizabeth; Song, Louis M. Wong Kee; Prabhu, Nayantara Coelho; Bruining, David Journal: American journal of gastroenterology Issue: Volume 111(2016)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study. (December 2021) Authors: Sands, Bruce; Pondel, Marc; Silver, Michael; Petersen, AnnKatrin; Wolf, Douglas; Panaccione, Remo; Loftus, Edward; Colombel, Jean-Frederic; Sturm, Andreas; D'Haens, Geert Journal: American journal of gastroenterology Issue: Volume 116:Supplement(2021)Advances in Inflammatory Bowel Diseases Annual Meeting Abstracts 1 Page Start: S8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. (February 2022) Authors: Peyrin-Biroulet, Laurent; Hart, Ailsa; Bossuyt, Peter; Long, Millie; Allez, Matthieu; Juillerat, Pascal; Armuzzi, Alessandro; Loftus, Edward V; Ostad-Saffari, Elham; Scalori, Astrid; Oh, Young S; Tole, Swati; Chai, Akiko; Pulley, Jennifer; Lacey, Stuart; Sandborn, William J; Aguilar, Humberto; Ah... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 2(2022) Page Start: 128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE. (22nd January 2022) Authors: Loftus, Edward; Pollack, Paul; Hunter, Theresa; Shan, Mingyang; Chan, Lai-Shan; Deckard, Deanilee; Cross, Raymond Journal: Inflammatory bowel diseases Issue: Volume 28(2022)Supplement 1 Page Start: S15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P-098 Serious Infections in Patients Treated with Certolizumab Pegol with or Without Corticosteroids: Pooled Safety Data from 15 Clinical Trials. (March 2016) Authors: Abraham, Bincy; Wolf, Doug; Regueiro, Miguel; Randall, Charles; Kosutic, Gordana; Spearman, Marshall; Coarse, Jason; Hasan, Iram; Loftus, Edward Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P-113 YI Body Fat and Skeletal Muscle Composition Differs in Crohn's Disease Patients Depending on Radiological Response to Medical Therapy. (March 2016) Authors: Deepak, Parakkal; Takahashi, Naoki; Fidler, Jeff; Barlow, John; Kolbe, Amy; Loftus, Edward; Bruining, David; Moynagh, Michael Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P-104 SECURE: An Observational Study of Certolizumab Pegol in Crohn's Disease—Events of Interest Analysis with 5869 Patient-Years at Risk. (March 2016) Authors: Lee, Scott; Wolf, Doug; Feagan, Brian; Lichtenstein, Gary; Andrews, Elizabeth; Stidham, Ryan; Aberra, Faten; Aguilar, Humberto; Kayhan, Cem; Kosutic, Gordana; Sen, David; Golembesky, Amanda; Hasan, Iram; Spearman, Marshall; Loftus, Edward Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P-099 Sex-Based Differences in Adverse Events of Crohn's Disease Patients Treated with Certolizumab Pegol: A Pooled Safety Analysis of 15 Studies. (March 2016) Authors: Kane, Sunanda; Loftus, Edward; Choudhary, Cuckoo; Randall, Charles; Ali, Tauseef; Kosutic, Gordana; Hasan, Iram; Coarse, Jason; Spearman, Marshall; Regueiro, Miguel Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗